Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

145.00GBp
27 Mar 2015
Change (% chg)

-- (--)
Prev Close
145.00p
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
422,710
52-wk High
158.75p
52-wk Low
113.25p

VEC.L

Chart for VEC.L

About

Vectura Group plc is a respiratory product development company. The Company focuses on the development of pharmaceutical therapies for treating airways-related diseases. The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, some of which are licensed to pharmaceutical... (more)

Overall

Beta: 0.09
Market Cap(Mil.): £584.61
Shares Outstanding(Mil.): 403.18
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 40.31 40.78
EPS (TTM): -0.02 -- --
ROI: -3.35 16.86 16.19
ROE: -3.65 17.40 17.04
Search Stocks

BRIEF-Vectura says NDAs for QVA149 and NVA237 accepted by FDA

* Acceptances trigger milestone payments to Vectura of $12.5 mln and $7.5 mln respectively Source text for Eikon: Further company coverage:

05 Mar 2015

BRIEF-Vectura says CEO to step down at the end of June

* Chris Blackwell will remain in his role until end of June 2015 and will assist board with search for his successor Source text for Eikon: Further company coverage:

03 Feb 2015

Britain's Vectura collaborates with Janssen in asthma, COPD

LONDON - Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday.

06 Jan 2015

Britain's Vectura collaborates with Janssen in asthma, COPD

LONDON, Jan 6 - Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday.

06 Jan 2015

BRIEF-Vectura signs global development and licence agreement with Janssen

* Vectura signs global development and licence agreement with Janssen in asthma/COPD

06 Jan 2015

BRIEF-Vectura's asthma drug meets main goal in mid-stage trial

* Investigational drug/device combination VR475 met primary endpoint and has shown significant clinical benefit in a phase IIb/III trial in severe asthma patients

11 Dec 2014

BRIEF-Vectura gets marketing nod for Airflusal Forspiro in Ireland and Czech Republic

* Approval in Ireland and Czech Republic for innovative respiratory inhaler airflusal forspiro

19 Nov 2014

BRIEF-Vectura names Andrew Oakley as CFO

* Oakley will succeed Paul Oliver as CFO, executive director, and company secretary effective from 1 January 2015 Source text for Eikon: Further company coverage:

18 Nov 2014

BRIEF-Vectura H1 rev up 14 pct

* Nva237 is expected to be filed in us by novartis in q4 2014 Source text for Eikon: Further company coverage:

18 Nov 2014

Earnings vs. Estimates

Search Stocks